WÓ 2005/034962 PCT/GB2004/004162

17

Claims

- Use of an anti-microbial agent and a metal chelator in
 the manufacture of a medicament for the modulation of lipid metabolism in the vascular system of an individual.
 - 2. Use according to claim 1 wherein the level of cholesterol is reduced in the vascular system of the individual.

Use according to claim 1 wherein the level of

25

apolipoprotein-B is reduced in the vascular system of the individual.

- 4. Use according to claim 3 wherein the condition is selected from the group consisting of hypercholesterolemia, hyperlipidemia, nephrotic syndrome, hypothyroidism, dysglobulinemia and Cushing syndrome.
- 20 5. Use according to claim 5 wherein said anti-microbial agent is a macrolide antibiotic.
 - 6. Use according to claim 5 wherein said anti-microbial agent is a azalide antibiotic
 - 7. Use according to claim 6 wherein said anti-microbial agent is azithromycin.
- 8. Use according to any one of the preceding claims wherein said metal chelator is a copper chelator.
 - 9. Use according to claim 8 wherein said copper chelator is acetylsalicylic acid.

WÓ 2005/034962 PCT/GB2004/004162

18

10. Use according to any of claims 1 to 9 wherein said medicament is a single composition comprising an antimicrobial agent and a metal chelator.

5

- 11. Use according to any of claims 1 to 9 wherein said medicament comprises separate preparations of the antimicrobial agent and metal chelator.
- 10 12. A method for modulating lipid metabolism in the vascular system comprising administering an anti-microbial agent and a metal chelator to an individual in need thereof.
- 13 A method according to claim 12 wherein the total level of cholesterol is reduced in the vascular system of the individual.
- 14. A method according to claim 12 or claim 13 wherein the level of apolipoprotein-B is reduced in the vascular system of the individual.
 - 15. A method according to any one of claims 12 to 14 wherein the condition is selected from the group consisting of hypercholesterolemia, hyperlipidemia, nephrotic syndrome,
- 25 hypothyroidism, dysglobulinemia and Cushing syndrome.
 - 16. A method according to any one of claims 12 to 15 wherein said anti-microbial agent is a macrolide antibiotic.
- 30 17. A method according to claim 16 wherein said antimicrobial agent is a azalide antibiotic

WÓ 2005/034962 PCT/GB2004/004162

19

- 18. A method according to claim 17 wherein said antimicrobial agent is azithromycin.
- 19. A method according to any one of claims 12 to 18 wherein5 said metal chelator is a copper chelator.
 - 20. A method according to any one of claims 12 to 19 wherein said copper chelator is acetylsalicylic acid.
- 10 21. A method according to claim according to any one of claims 12 to 20 wherein anti-microbial agent and the metal chelator are administered simultaneously.
- 22. A method according to any one of claims 12 to 20 wherein anti-microbial agent and the metal chelator are administered sequentially.
- 23. A pharmaceutical composition comprising an anti-microbial agent and a metal-chelator for use in the modulation of lipid metabolism.
 - 24. A pharmaceutical composition according to claim 23 comprising azithromycin and aspirin
- 25 25. A method of preparing a composition for use in the modulation of lipid metabolism comprising; admixing a anti-microbial agent and a metal chelator with a pharmaceutically acceptable excipient.
- 30 26, A method according to claim 25 wherein the anti-microbial agent is azithromycin and the metal chelator is acetylsalicylic acid.